PA
COGT icon

Profund Advisors’s Cogent Biosciences COGT Stock Holding History

Profund Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Sell
46,226
-10,825
-19% -$379K 0.05% 222
2026
Q1 		$2.2M Buy
57,051
+14,302
+33% +$528K 0.08% 181
2025
Q4 		$1.52M Buy
42,749
+9,666
+29% +$272K 0.05% 266
2025
Q3 		$475K Buy
33,083
+12,926
+64% +$153K 0.02% 533
2025
Q2 		$145K Sell
20,157
-14,738
-42% -$81.7K 0.01% 944
2025
Q1 		$209K Buy
34,895
+3,306
+10% +$25.9K 0.01% 889
2024
Q4 		$246K Buy
31,589
+8,167
+35% +$81.4K 0.01% 876
2024
Q3 		$253K Sell
23,422
-11,072
-32% -$108K 0.01% 905
2024
Q2 		$291K Sell
34,494
-73,992
-68% -$561K 0.01% 733
2024
Q1 		$729K Buy
108,486
+60,917
+128% +$377K 0.03% 447
2023
Q4 		$280K Buy
47,569
+14,366
+43% +$110K 0.01% 818
2023
Q3 		$324K Sell
33,203
-4,784
-13% -$56.7K 0.02% 628
2023
Q2 		$450K Sell
37,987
-7,275
-16% -$83.5K 0.02% 544
2023
Q1 		$488K Buy
+45,262
New +$579K 0.03% 510

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Profund Advisors's COGT Position: Q2 2026 in Review

Profund Advisors reduced its Cogent Biosciences (COGT) stake by 19% in Q2 2026, selling an estimated $379K and leaving 46,226 shares worth $1.79M. The position accounts for 0.05% of the portfolio, ranked #222.

Profund Advisors first reported a position in COGT in Q1 2023 and has held it in 14 quarters since. The position peaked at $2.2M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Profund Advisors held 46,226 shares of Cogent Biosciences worth $1.79M as of Q2 2026.
  • Profund Advisors sold 10,825 Cogent Biosciences shares in Q2 2026, an estimated $379K.
  • Cogent Biosciences made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #222 holding.
  • Profund Advisors first reported a position in Cogent Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Profund Advisors's Cogent Biosciences position peaked at $2.2M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.